TCR Mimic Monoclonal Antibody Targets a Specific Peptide/HLA Class I Complex and Significantly Impedes Tumor Growth In Vivo Using Breast Cancer Models

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Immunology

• Publication date

  2010-01-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.0902414PMID 20065111
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of novel tumor antigens with patient-derived immune-selected antibodies

  2009cited by this paper
• Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma1

  2009cited by this paper
• Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

  2008cited by this paper
• Factors determining antibody distribution in tumors.

  2008cited by this paper
• Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.

  2008cited by this paper
• Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis

  2008cited by this paper
• Assessing vaccine potency using TCRmimic antibodies.

  2008cited by this paper
• Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

  2008cited by this paper
• Her2-positive breast cancer: herceptin and beyond.

  2008cited by this paper
• Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells.

  2008cited by this paper
• Targeting TARP, a novel breast and prostate tumor‐associated antigen, with T cell receptor‐like human recombinant antibodies

  2008cited by this paper
• Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen1

  2007cited by this paper
• Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes.

  2007cited by this paper
• Identification of T-cell epitopes for cancer immunotherapy

  2007cited by this paper
• Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

  2007cited by this paper
• Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis

  2007cited by this paper
• Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases

  2007cited by this paper
• Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).

  2007cited by this paper
• Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers

  2007cited by this paper
• Human chorionic gonadotropin (hCG) up-regulates wnt5b and wnt7b in the mammary gland, and hCGbeta transgenic female mice present with mammary Gland tumors exhibiting characteristics of the Wnt/beta-catenin pathway activation.

  2007cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

  2006cited by this paper
• Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death

  2006cited by this paper
• Identification of Candidate Target Antigens for Antibody-Based Immunotherapy in Childhood B-Cell Precursor ALL

  2006cited by this paper
• Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing1

  2006cited by this paper
• In Vitro and In Vivo Characterization of a Novel Antibody-Like Single-Chain TCR Human IgG1 Fusion Protein1

  2005cited by this paper
• Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions

  2005cited by this paper
• The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• Human chorionic gonadotropin in cancer.

  2004cited by this paper
• Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments

  2004cited by this paper
• Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma

  2004cited by this paper
• A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity

  2004cited by this paper
• Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.

  2004cited by this paper
• Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen 1

  2003cited by this paper
• Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression.

  2003cited by this paper
• Direct Phenotypic Analysis of Human MHC Class I Antigen Presentation: Visualization, Quantitation, and In Situ Detection of Human Viral Epitopes Using Peptide-Specific, MHC-Restricted Human Recombinant Antibodies1

  2003cited by this paper
• Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

  2002cited by this paper
• Transgenic mice harboring murine luteinizing hormone receptor promoter/beta-galactosidase fusion genes: different structural and hormonal requirements of expression in the testis, ovary, and adrenal gland.

  2002cited by this paper
• Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity

  2002cited by this paper
• Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.

  2002cited by this paper
• Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

  2000cited by this paper
• Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells

  1999cited by this paper
• An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice.

  1998influential reference
• Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma.

  1998cited by this paper
• gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

  1998cited by this paper
• Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

  1998cited by this paper
• Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

  1997cited by this paper
• Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

  1996cited by this paper
• Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.

  1996cited by this paper
• Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

  1996cited by this paper
• A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

  1996cited by this paper
• Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

  1995cited by this paper
• Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

  1994cited by this paper
• Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.

  1994cited by this paper
• Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

  1994cited by this paper
• Effect of reconstituted basement membrane components on the growth of a panel of human tumour cell lines in nude mice.

  1993cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor.

  1991cited by this paper
• Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

  1990cited by this paper
• Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

  1989cited by this paper

• Treponema denticola major surface protein (Msp): a key player in periodontal pathogenicity and immune evasion

  2025cites this paper
• Immunotherapy targeting a leader sequence cathepsin G-derived peptide

  2025cites this paper
• T cell receptor mimic CAR T cells targeting cathepsin G signal peptide

  2025cites this paper
• Challenges and solutions for therapeutic TCR‐based agents

  2023cites this paper
• Self-Induced Back-Action Actuated Nanopore Electrophoresis (SANE) Sensor for Label-Free Detection of Cancer Immunotherapy-Relevant Antibody-Ligand Interactions.

  2022cites this paper
• Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

  2021cites this paper
• Using dynamic cell communication improves treatment strategies of breast cancer

  2021cites this paper
• Nanoparticle‐Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment

  2020cites this paper
• Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen

  2019cites this paper
• Opportunities and Challenges for Antibodies against Intracellular Antigens

  2019cites this paper
• Detection of specific antibody-ligand interactions with a self-induced back-action actuated nanopore electrophoresis sensor

  2019cites this paper
• T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins

  2019cites this paper
• Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies

  2019cites this paper
• T Cell Receptor Mimic Antibodies

  2018cites this paper
• Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.

  2016cites this paper
• Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late

  2016cites this paper
• T cell receptor mimic antibodies for cancer therapy

  2016cites this paper
• Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!

  2016cites this paper
• Opportunities and challenges for TCR mimic antibodies in cancer therapy

  2016cites this paper
• Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer

  2015cites this paper
• T Cell Receptor Engineering and Analysis Using the Yeast Display Platform.

  2015cites this paper
• Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

  2015cites this paper
• Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

  2015cites this paper
• Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes

  2015cites this paper
• Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

  2014cites this paper
• Engineering T Cells to Target Tumor Cells

  2014cites this paper
• TCR-MHC/peptide interaction: prospects for new anti-tumoral agents.

  2014cites this paper
• Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

  2013cites this paper
• T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

  2013cites this paper
• Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody

  2013cites this paper
• Approaching untargetable tumor-associated antigens with antibodies

  2013cites this paper
• A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma.

  2013cites this paper
• HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

  2013cites this paper
• Use of T Cell Receptor-like Antibody Fragments for Imaging and Immunotherapy

  2013cites this paper
• Identification of a New Cytotoxic T-Cell Epitope p675 of Human Telomerase Reverse Transcriptase

  2012cites this paper
• Inhibitory effects of 5-Aza-2′-deoxycytidine and trichostatin A in combination with p53-expressing adenovirus on human laryngocarcinoma cells

  2012cites this paper
• Potential antitumor applications of a monoclonal antibody specifically targeting human papilloma virus 16 E749–57 peptide

  2012cites this paper
• T Cell Receptor-Like Recognition of Tumor In Vivo by Synthetic Antibody Fragment

  2012cites this paper
• T-cell-receptor-like antibodies – generation, function and applications

  2012cites this paper
• Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains

  2011cites this paper
• An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer

  2011cites this paper
• TCR Mimic Monoclonal Antibodies Induce Apoptosis of Tumor Cells via Immune Effector-Independent Mechanisms

  2011cites this paper
• TCR-like Biomolecules Target Peptide/MHC Class I Complexes on the Surface of Infected and Cancerous Cells

  2011cites this paper
• An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

  2011cites this paper
• Single chain MHC trimer (SCT)-based DNA vaccines for pathogen protection

  2011cites this paper
• Expanding the Targets Available to Therapeutic Antibodies via Novel Disease-specific Markers

  2011cites this paper
• Effector-Independent Mechanisms Apoptosis of Tumor Cells via Immune TCR Mimic Monoclonal Antibodies Induce

  2011cites this paper
• A novel vascular targeting strategy for brain‐derived endothelial cells using a TCR mimic antibody

  2010influential citation
• Engineering human single-chain T cell receptors

  2010cites this paper
• Target for Invasive Breast Cancer Migration Inhibitory Factor Is a Therapeutic an Hla-presented Fragment of Macrophage

  year unknowncites this paper